Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.
VERIFY
Phase 3 small_molecule active
Quick answer
Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted. for Polycythemia Vera is a Phase 3 program (small_molecule) at Protagonist Therapeutics, Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Protagonist Therapeutics, Inc
- Indication
- Polycythemia Vera
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active